A person is deemed to have a significant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership of $$10 000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person s gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. *Writing committee members are required to recuse from voting on sections to which their specific relationships with industry and other entities could apply. Section numbers apply to the full-text guideline. Significant relationship. No financial benefit. The current guideline was developed during the transition in RWI policy and occurred over an extended period of time. In the interest of transparency, we provide full information on RWI existing over the entire period of guideline development, including delineation of relationships that expired .24 months before the guideline was finalized. CV indicates cardiovascular; DSMB, data safety and monitoring board; and SAQ, Seattle Angina Questionnaire. Appendix 2. Reviewer Relationships With Industry and Other Entities (Relevant): 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guidelines for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease Reviewer Representation Consultant Speaker Ownership/ Partnership/ Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Ralph G. Brindis Official Reviewer ACCF Board of Trustees None None None None None None Timothy D. Henry Official Reviewer AHA CV Therapeutics Sanofi-aventis None None Baxter* CV Therapeutics* None None Judith S. Hochman Official Reviewer ACCF/AHA Task Force on Practice Guidelines Eli Lilly GlaxoSmithKline None None Johnson & Johnson Merck Robert H. Jones Official Reviewer STS None None None None None None Janet B. 